Medicus Pharma Ltd.
MDCX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.63% | 42.52% | 54.76% | 52.30% | 998.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.86% | 74.65% | 131.86% | 123.03% | 948.53% |
| Operating Income | -80.86% | -74.65% | -131.86% | -123.03% | -948.53% |
| Income Before Tax | -283.32% | -63.51% | -103.24% | -86.15% | -111.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283.32% | -63.51% | -103.24% | -86.15% | -111.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283.32% | -63.51% | -103.24% | -86.15% | -111.28% |
| EBIT | -80.86% | -74.65% | -131.86% | -123.03% | -948.53% |
| EBITDA | 69.38% | 12.34% | -364.57% | -- | -- |
| EPS Basic | -103.98% | 43.80% | 38.27% | 49.11% | 50.59% |
| Normalized Basic EPS | -60.93% | 43.59% | 37.27% | 48.31% | 52.14% |
| EPS Diluted | -103.98% | 43.80% | 38.27% | 49.11% | 50.59% |
| Normalized Diluted EPS | -60.93% | 43.59% | 37.27% | 48.31% | 52.14% |
| Average Basic Shares Outstanding | 66.80% | 79.62% | 105.33% | 166.77% | 342.60% |
| Average Diluted Shares Outstanding | 66.80% | 79.62% | 105.33% | 166.77% | 342.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |